Baseline adiponectin levels do not influence the response to pioglitazone in act now

Devjit Tripathy, Stephen C. Clement, Dawn C. Schwenke, Mary Ann Banerji, George A. Bray, Thomas A. Buchanan, Amalia Gastaldelli, Robert R. Henry, Abbas E. Kitabchi, Sunder Mudaliar, Robert E. Ratner, Frankie B. Stentz, Nicolas Musi, Peter D. Reaven, Ralph A. De Fronzo

Research output: Contribution to journalArticle

8 Scopus citations

Abstract

OBJECTIVE Plasma adiponectin levels are reduced in type 2 diabetes mellitus (T2DM) and other insulin-resistant states.We examined whether plasma adiponectin levels at baseline and after pioglitazone treatment in impaired glucose tolerance (IGT) subjects were associated with improved insulin sensitivity (SI) and glucose tolerance status. RESEARCH DESIGN AND METHODS A total of 602 high-risk IGT subjects in ACT NOW were randomized to receive pioglitazone or placebo with a median follow-up of 2.4 years. RESULTS Pioglitazone reduced IGT conversion to diabetes by 72% in association with improved β-Cell function by 64% (insulin secretion/insulin resistance index) and increased tissue sensitivity by 88% (Matsuda index). In pioglitazone-treated subjects, plasma adiponectin concentration increased threefold from1360.5 to 386 2.5 mg/mL (P < 0.001) and was strongly correlated with the improvement in SI (r = 0.436, P < 0.001) and modestly correlated with glucose area under the curve during oral glucose tolerance test (r = 0.238, P < 0.005) and insulin secretion/ insulin resistance index (r = 0.306, P < 0.005). The increase in adiponectin was a strong predictor of reversion to normal glucose tolerance and prevention of T2DM. In the placebo group, plasma adiponectin did not change and was not correlated with changes in glucose levels. There was an inverse association between baseline plasma adiponectin concentration and progression to diabetes in the placebo group but not in the pioglitazone group. CONCLUSIONS Baseline adiponectin does not predict the response to pioglitazone. The increase in plasma adiponectin concentration after pioglitazone therapy in IGT subjects is strongly related to improved glucose tolerance status and enhanced tissue sensitivity to insulin.

Original languageEnglish (US)
Pages (from-to)1706-1711
Number of pages6
JournalDiabetes care
Volume37
Issue number6
DOIs
StatePublished - Jun 2014

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Advanced and Specialized Nursing

Fingerprint Dive into the research topics of 'Baseline adiponectin levels do not influence the response to pioglitazone in act now'. Together they form a unique fingerprint.

  • Cite this

    Tripathy, D., Clement, S. C., Schwenke, D. C., Banerji, M. A., Bray, G. A., Buchanan, T. A., Gastaldelli, A., Henry, R. R., Kitabchi, A. E., Mudaliar, S., Ratner, R. E., Stentz, F. B., Musi, N., Reaven, P. D., & De Fronzo, R. A. (2014). Baseline adiponectin levels do not influence the response to pioglitazone in act now. Diabetes care, 37(6), 1706-1711. https://doi.org/10.2337/dc13-1745